Squarepoint Ops LLC Has $1.53 Million Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Squarepoint Ops LLC increased its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 143.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 126,389 shares of the company’s stock after buying an additional 74,452 shares during the quarter. Squarepoint Ops LLC’s holdings in Y-mAbs Therapeutics were worth $1,527,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Y-mAbs Therapeutics in the 4th quarter valued at approximately $562,000. Ameritas Investment Partners Inc. lifted its stake in Y-mAbs Therapeutics by 39.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after purchasing an additional 1,056 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Y-mAbs Therapeutics by 8.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock valued at $345,000 after buying an additional 1,657 shares in the last quarter. Boston Partners bought a new stake in shares of Y-mAbs Therapeutics during the first quarter worth $556,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of Y-mAbs Therapeutics by 8.0% during the second quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock worth $1,461,000 after buying an additional 8,974 shares in the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 65,000 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the sale, the insider now owns 97,681 shares in the company, valued at $1,315,763.07. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Thomas Gad sold 65,000 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $13.47, for a total transaction of $875,550.00. Following the transaction, the insider now directly owns 97,681 shares of the company’s stock, valued at $1,315,763.07. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Joris Wilms sold 5,000 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the sale, the chief operating officer now owns 30,600 shares of the company’s stock, valued at $449,514. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 100,000 shares of company stock valued at $1,338,100. Corporate insiders own 21.50% of the company’s stock.

Y-mAbs Therapeutics Stock Performance

NASDAQ:YMAB opened at $14.16 on Friday. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $4.69 and a fifty-two week high of $20.90. The company has a 50 day simple moving average of $13.00 and a two-hundred day simple moving average of $13.27. The company has a market capitalization of $631.11 million, a PE ratio of -28.90 and a beta of 0.70.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). The firm had revenue of $22.80 million for the quarter, compared to the consensus estimate of $23.09 million. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. During the same period in the prior year, the business earned ($0.14) EPS. Research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.57 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on YMAB. BMO Capital Markets cut their price objective on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Canaccord Genuity Group reiterated a “buy” rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Wedbush reissued an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Y-mAbs Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $21.14.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.